APR 08, 2015 04:00 PM PDT

New Therapeutic Option Available for Select Treatment Resistant Lung Cancer Patients

Novartis announces that Health Canada has issued a marketing authorization with conditions for Zykadia (ceritinib), a lung cancer treatment that addresses an unmet medical need for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib.

"The majority of ALK+ patients are younger and have never smoked, which represents a demographic that many are surprised to hear associated with this devastating illness. Until recently, treatment options have been limited." states Dr. Jeffrey Rothenstein, MD, FRCPC. "Zykadia represents an important new option for patients who relapse after starting initial therapy."

NSCLC can be characterized based on a patient's genetic abnormalities that are causing the cancer growth and researchers have identified over 12 of these genetic abnormalities. Of those, 2 to 7 percent are driven by a rearrangement of the ALK gene, which increases the growth of cancer cells and can be identified by a molecular test of the cancer tumor.

"Developments in targeted gene therapy such as treatments targeting ALK rearrangements are helping us move towards personalized medicine," states Shem Singh, Executive Director, Lung Cancer Canada. "Molecular testing should be done on a patient's tumor as soon as there is a NSCLC lung cancer diagnosis. This will help patients and physicians identify the best treatment as quickly as possible."

The marketing authorization with conditions for Zykadia was based on a pivotal Phase 1 trial that included 163 patients with metastatic ALK+ NSCLC who had received prior treatment with crizotinib. Among these patients, Zykadia achieved an overall response rate of 54.6 percent and the median duration of response was 7.4 months.

"Novartis is committed to ongoing research in the area of lung cancer with the goal of developing new medicines to help improve the lives of cancer patients and their families. We are proud to be at the forefront of innovative research into personalized treatments that may help bring new solutions to more patients," said Fionnuala Doyle, General Manager, Oncology, Novartis Pharmaceuticals Canada Inc.

Source: Novartis Canada
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
AUG 21, 2018
Immunology
AUG 21, 2018
T cells Trapped by Brain Cancer
Brain tumors prevent T cells from escaping the bone marrow by altering levels of the S1P1 protein....
AUG 21, 2018
Cancer
AUG 21, 2018
Theranostics.....Heard of it?
Theranostics is an emerging field that combines therapeutics and diagnostic capabilities into one opportunity for treatment of diseases, especially cancer....
OCT 25, 2018
Health & Medicine
OCT 25, 2018
Sedentary Lifestyle More Deadly Than Smoking
A number of recent studies have found that first cardiovascular associations with regular high-intensity exercise. These studies......
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 26, 2018
Cell & Molecular Biology
NOV 26, 2018
New Insight Into the Machinery That Drives Cell Death
When cells are worn out and damaged or diseased, they can initiate a self-destruct sequence called apoptosis....
Loading Comments...